
## **Global Blood Therapeutics**

# Sickle Cell Pediatric Enrollment



Ted Love, MD

Bella Oguno, MPH





The information contained in this presentation represents the views, experience, and opinions of the presenters and does not necessarily represent the views or opinions of Global Blood Therapeutics, Inc., or its successor in interest Pfizer, Inc.

The content of this presentation has been made available for informational and educational purposes only. Neither the presenters, Global Blood Therapeutics, nor Pfizer make any representation or warranties with respect to the accuracy, applicability, fitness, or completeness of the presentation content.






### **GBT440-032:**

A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Voxelotor (GBT440) in Pediatric Participants with Sickle Cell Disease (HOPE Kids 2) WHERE?



#### < 10 % Enrollment

#### > 80 % Enrollment



Created with mapchart.net

Created with mapchart.net

## HOW?



#### Key Stakeholders

- Physicians
- Parents/Caregivers
- Regulators
- Partners
- Key Opinion Leaders
- Vendors
- Internal Team



### HOW?



